{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034551","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.884120+00:00","generated_at":"2026-05-30T01:35:06.037469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dyadic Q3 2024 revenue jumps to $1.96M; net loss narrows to $0.20M","bullets":["Revenue of ~$1.958M vs $397K in Q3 2023, driven by $1M Proliant milestone and $425K Inzyme success fee.","Net loss of $203K vs $1.614M a year ago; operating loss fell to $203K from $1.720M.","Cash & investment-grade securities at $10.0M as of Sep 30, 2024, up from $7.3M at Dec 31, 2023.","Received $1M milestone from Proliant for animal-free recombinant albumin; first product launch expected H1 2025.","Advanced C1-produced Mpox antigen with ViroVax (4.5 g/L in 7 days); preclinical studies start Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034551","json":"https://secwatch.observer/filing/0001437749-24-034551.json","markdown":"https://secwatch.observer/filing/0001437749-24-034551.md","text":"https://secwatch.observer/filing/0001437749-24-034551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924034551/0001437749-24-034551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924034551/dyai20240905_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:35:06.037469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}